In the current era of immune checkpoint inhibitors (ICIs), the role and timing of nephrectomy for kidney residual disease for patients with a radiological complete response (CR) at metastatic sites are still unknown.
Our study showed that tivozanib as third-line or fourth-line therapy improved progression-free survival and was better tolerated compared with sorafenib in patients with metastatic renal cell carcinoma.
